Studies have shown that active fund managers routinely underperform the S&P500 index*​

Cardiol Therapeutics Inc. (NASDAQ: CRDL)

CRDL Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
279.50%

CRDL Stock Analysis

CRDL PE Ratio:

CRDL PEG Ratio: Not Available

CRDL Forward EPS Growth (12 month): 0.00%

CRDL PS Ratio:

CRDL PSG Ratio: Not Available

CRDL Forward Revenue Growth (12 month): 0.00%

CRDL Articles

No data was found